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Summary 
Tumor necrosis factor (TNF) c~, a potent inhibitor of endothelial cell growth in vitro, is angiogenic 
in vivo. Therefore, it was suggested that the angiogenic properties of this agent might be consequent 
to the production of secondary mediators. Since TNF-ol stimulates the synthesis of platelet-activating 
factor (PAF) by monocytes and endothelial cells,  we investigated the possible involvement of 
PAF in the angiogenic effect of TNF-c~. Angiogenesis was studied in a murine model in which 
Matrigel was used as a vehicle for the delivery of mediators. In this model the angiogenesis induced 
by TNF-ot was shown to be inhibited by WEB 2170, a specific PAP receptor antagonist. Moreover, 
in mice injected with TNF-ot, PAF was detected within the Matrigel, 6 and 24 h after TNF-o~ 
injection. The synthesis of PAF within the Matrigel was concomitant with the early migration 
of endothelial cells and infiltration of monocytes. No infiltration of lymphocytes or polymorpho- 
nuclear leukoeytes was observed. Synthetic PAF as well as PAF extracted and purified from mice 
challenged with TNF-ot induced a rapid angiogenic response, inhibited by WEB 2170.  These 
results suggest that the angiogenic effect of TNF-c~ is, at least in part, mediated by PAF synthesized 
from monocytes and/or endothelial cells infiltrating the Matrigel plug. 
ngiogenesis is important in wound healing, tumor growth, 
and inflammation, and activated monocytes/macrophages 
are key angiogenesis effector cells in these settings (1, 2). The 
array of mediators involved in the initiation and progression 
of angioproliferative disease processes remains to be precisely 
defined. It has been recently reported that TNF-ot/cachectin 
(TNF-o  0, a polypeptide hormone with a wide range of bio- 
logical activities (3), is angiogenic in vivo (4, 5). Since TNF-~ 
is a potent inhibitor of endothelial cell growth in vitro (4), 
it was suggested that the angiogenic properties of this agent 
might be consequent to the production of secondary medi- 
ators. Several in vitro studies (6-8) have established an inter- 
action between TNF-ot and platelet-activating factor (PAF), 
a phospholipid mediator of inflammation. PAF belongs to 
the  structurally  related  family  of  acetylated  alkyl  phos- 
phoglycerides and possesses diverse and potent biological prop- 
erties (9-11).  TNF-ot induces PAF synthesis from several cell 
types including monocytes/macrophages, polymorphonuclear 
neutrophils, and endothelial cells (6, 7).  PAF, in turn, was 
shown to  stimulate  the production of TNF-c~ by mono- 
cytes/macrophages (8). As the administration of PAF to ex- 
perimental animals reproduces several aspects of TNF-c~ in- 
fusion (3), it seems possible that PAF mediates some of the 
biological properties of TNF-o~.  Aside from being the pri- 
mary mediator of endotoxic shock and from being cytostatic 
or cytotoxic for certain tumor cells, TNF-c~ possesses a number 
of biological activities that are relevant to the development 
of inflammatory reactions (3), including the ability to stimulate 
in vivo the neoangiogenesis (4, 5). Whether these biological 
properties of TNF-ot depend on interactive activities between 
TNF-ot and PAF remains unknown. However preliminary 
results indicate that PAF mediates, at least in part,  the in- 
creased permeability of endothelial monolayer (12) and the 
contraction of mesangial cells (13) induced by TNF-o~ as well 
as the delayed PMN adhesion to and migration across  the 
endothelium activated by TNF-cr (14). Other properties of 
TNF-ot such as the cytotoxicity and the early adhesion of 
PMN to stimulated endothelium seem not to involve PAF 
as secondary mediator (15).  The aim of this study was to 
evaluate whether the angiogenic property of TNF-ot may de- 
pend on PAF synthesis. The results of this study indicate that 
the angiogenic effect of TNF-ot in a murine model in which 
Matrigel is used as a vehicle for the delivery of mediators 
(16), depends, at least in part, on the synthesis of PAF. In- 
deed, PAF was synthesized within the Matrigel during the 
angiogenic response to TNF-ot,  furthermore, WEB  2170, 
a specific PAF receptor antagonist (17), inhibited this angio- 
genic response, and PAF itself was found to be angiogenic. 
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Reagents.  Matrigel basement membrane matrix was obtained 
from Becton Dickinson Labware (Bedford, MA). Human recom- 
binant TNF-cr  heparin (from porcine intestinal mucosa) and pro- 
tamine sulfate were provided by Sigma Chemical Co. (St.  Louis, 
MO).  Synthetic  C16  PAF  (1-hexadecyl-2-acetyl-sn-glyceryl-3- 
phosphorylcholine) was obtained from Bachem Feinchemikalien 
(Bubendorf, Switzerland). WEB 2170 (Boehringer, Ingelheim KG, 
Germany) was used as PAF receptor antagonists (17). Anti-mouse 
T  cell serum, anti-L3/T4 and Ly2 mAbs, and anti-Mac-1 FITC- 
conjugated mAbs were purchased from Cedarlane Laboratories Ltd., 
Hornby,  ON,  Canada).  FITC-conjugated  anti-rabbit  IgG and 
anti-mouse IgG were obtained from Cappd Laboratories  (Cochran- 
ville, PA). Rabbit anti-human yon Willebrand Factor (vWF) was 
obtained from Sigma Chemical Co. Silica gel 60F254 TLC plates 
were obtained from Merck (Darmstadt, Germany). ~Porasil HPLC 
columns were provided from Millipore Corp. Waters Chromato- 
graphic (Milford,  MA). 
Murine Angiogenesis Assay.  Female C57 mice were used at 6-8 
wk of age. Angiogenesis was assayed as growth of blood vessels 
from subcutaneous tissue into a solid gel of basement membrane 
containing the test sample (16, 18). Matrigel (8.13 mg/ml), in liquid 
form at 4~  was mixed with the experimental substances and in- 
jected (0.5 ml) into the abdominal subcutaneous  tissue of mice, 
along the peritoneal midline.  Matrigel rapidly forms a solid gel 
at body temperature, trapping the factors to allow slow release and 
prolonged exposure to surrounding tissues. At various times, mice 
were subsequently killed and gels were recovered and processed for 
histology. Typically, the overlying skin was removed, and gels were 
cut out by retaining the peritoneal lining for support. Part of the 
tissue was fixed in 10% buffered formalin and embedded in paraffin. 
Sections cut at 3 ~m and stained with hematoxylin and eosin were 
studied by light microscopy. Other sections, obtained from frozen 
tissue cut with a cryostat, were stained for nonspecific esterase ac- 
tivity (19,  20) or processed for immunofluorescence microscopy, 
performed as previously described (21).  Vessel area and the total 
Matrigel area were planimetricaUy assessed from stained sections, 
as described by Kibbey et al. (18). Only those structures possessing 
a patent lumen and containing ILBC were considered vessels. Results 
were expressed as percentage _+ SEM of the vessel area to the total 
Matrigel area. 
Experiment Protocol.  The angiogenic effect of various doses of 
TNF-ct (1-10 rig) in 0.5 ml of Matrigel was studied at different 
times and in the absence or presence of different doses of heparin 
(6.4-64 U/ml). In selected experiments, the effect of WEB 2170, 
(17) on TNF-ct-induced  angiogenesis was evaluated. WEB 2170 
was included in the Matrigel plug (final concentration, 250 ng/ml) 
and injected intraperitoneally (10 mg/kg) 30 min before the sub- 
cutaneous injection and daily for 6 d. The direct angiogenic effect 
of synthetic PAF and PAF extracted and purified from Matrigel 
plugs of mice challenged with TNF-ct was also  studied. 
PAF Assay.  PAF extracted and purified by the Matrigel plugs 
obtained from mice was quantitated by bioassay on washed rabbits 
platelets (22) and by HPLC tandem mass spectrometry (MS) (23). 
PAF bioactivity, tested after extraction (24) and purification by TLC 
and HPLC (25), was characterized by comparison with synthetic 
PAF according to the following criteria:  (a) induction of platelet 
aggregation by a pathway independent of both the ADP- and ara- 
chidonic acid/thromboxane A2-mediated pathway; (b) specificity 
ofplatelet aggregation as inferred from the inhibitory effect of PAF 
receptor antagonist WEB 2170 (5/~M); (c) TLC and HPLC chro- 
matographic behavior and physicochemical characteristics such as 
inactivation by strong bases and 5-min heating in boiling water; 
(d) MS spectra obtained at the same retention time of C16 syn- 
thetic PAF (29.9-30.2 rain) with a fragmentation pattern charac- 
terized by a molecular ion (mass/atomic number ratio [m/z] 523) 
and a fragment corresponding to phosphocholine (m/z 183). The 
methods used were previously described in detail (23,  25). 
Results 
Matrigel containing 64 U/m1 of heparin and various doses 
of TNF-tx, TNF-tx plus WEB 2170, or vehicle alone, as con- 
trol, was injected subcutaneously into mice. The histologic 
and morphometric analysis of Matrigel plugs was performed 
at death 6  d  later.  As shown in Fig.  1 A,  TNF-ct induced 
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Figure  1.  Effect  of PAF receptor antagonist WEB 2170 (A) and heparin 
(B) on TNF-c~-induced angiogenesis. (A) Matrigel containing 64 U/ml 
heparin was mixed with TNF-oe, TNF-o~ + WEB 2170, or vehicle alone 
as a control and was injected subcutaneously into mice. (B) Matrigel con- 
taining 10 ng TNF-ct without or with 6.4 or 64 U/ml heparin was used. 
After 6 d, mice were killed and the Matrigel plugs were excised  and processed 
for light and immunofluorescence microscopy. Quantitation of neovascu- 
larization was performed on hematoxylin-eosin stained histologic sections 
as described in Materials and Methods, and results were expressed as per- 
cent + SEM of the vessel area to the total Matrigel area. Each individual 
experimental group included five mice. ANOVA with Newman-Keul's 
muhi-comparison test was performed: control vs. TNF-oe 5 or 10 ng (*) 
p <0.05; WEB 2170 + TNF-o~ 5 ng vs. TNF-oe 5 ng (.4-)  p <0.05; WEB 
2170  +  TNF-c~ 10 ng vs. TNF-c~ 10 ng (w  <0.05~TNF-tx without 
heparin vs. TNF-~ + heparin 6.4 or 64 U/ml (IJ)P <0.05. Similar results 
were obtained when quantitation of neovascularization was performed on 
slides stained by immunofluorescence with vWF antibodies. 
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trols and significantly reduced in mice receiving Matrigel con- 
taining TNF-oe and WEB 2170 (250 ng/ml) followed by daily 
intraperitoneal injection of WEB 2170 (10 mg/kg die). The 
optimal angiogenic effect of TNF-o~ required the concentra- 
tion of 64 U/ml of heparin (Fig.  1 B),  as described for the 
basic fibroblast growth factor (16). However, the neoangio- 
genesis was also observed at a concentration of 6.4 U/ml of 
heparin,  compatible with that  observed in inflamed tissues 
(26).  In preliminary time course experiments,  it was estab- 
lished that maximal vascularization of Matrigel occurred at 
day 6. After 24 h, penetration into the Matrigel of cords of 
vWF-positive endothelial cells (Fig. 2, A  and B) and of scat- 
tered Mac-1  (Fig.  2 A,  inset) esterase positive cells was ob- 
served in mice treated with TNF-ct but not in controls (Fig. 
2  C).  Canalization  of vessels progressively increased in the 
following days and reached its maximal at day 6  (Figs.  2 D 
and 3 A), with formation of  linear or microaneurismatic struc- 
tures containing RBCs  and leukocytes (Fig. 3 A).  Sections 
of the gel were stained with anti-vWF antibodies to confirm 
the presence of endothelial cells in association with the vessels 
(Fig. 2 D). Infiltration into the Matrigel of cells positive for 
pan-T lymphocyte markers or for L3/T4 or Ly2 antigens as 
well as of PMN  was  never observed.  In contrast,  scattered 
Mac-l-esterase positive cells were also infiltrating the Matrigel 
at day 6,  indicating the presence of few monocytes/macro- 
phages in the extravascular matrix.  As  shown in Fig.  3 B, 
WEB 2170 markedly reduced the vascularization of Matrigel 
induced by TNF-o~ at day 6.  In selected experiments,  PAF 
was extracted from Matrigel 6 h, 24 h, and 6 d after the be- 
ginning of the experiment. PAF was detected at 6 and 24 h 
in mice injected with Matrigel containing TNF-o~ but not 
in controls (Fig.  4).  When  the animals were injected with 
Matrigel containing 5  ng  synthetic PAF,  an angiogenic re- 
sponse was  observed (Fig.  5,  Fig.  3,  C  and D).  Moreover, 
the amount of biological PAF produced after the stimulation 
Figure  2.  Histological analysis of Matrigel plugs. Hematoxylin-eosin 
(A) and vWF antibody-stained  section  (B) of  Matrigel containing  64 U/ml 
heparin and 10 ng TNF-c~  excised  24 h after injection. Penetration  of  cords 
of vWF-positive  endothelial cells into Matrigel is evident. Scattered  Mac- 
1-positive  monocytes  (inset,  A) are seen  in the Matrigel containing TNF-ct 
at 24 h. (C) Hematoxylin-eosin-stained  section  of  control Matfigel  without 
TNF-c~, excised  24 h after injection. (D) Endothelial cells, stained by in- 
direct immunofluorescence  for vWF, underlining the lumen of a large 
branched vessel in sections of Matrigel containing 64 U/ml heparin and 
10 ng TNF-o~  excised  6 d after the injection. (A)  xl00, inset x400; (B) 
x 250; (C)  x 100; (D)  x 250. 
Figure 3.  (A) Hematoxylin-eosin-stained  sections  of  Matrigel  containing 
64 U/ml heparin and 10 ng TNF-a excised  6 d after the injection. Canal- 
ized vessels and microaneurismatic  structures containing RBCs and leu- 
kocytes  are seen. (B) Inhibitory effect  of WEB 2170 on neovascularization 
of Matrigel containing 64 U/ml heparin and 10 ng TNF-ol excised 6 d 
after  injection. (C and D) Sections  of  Matrigel containing 64 U/ml heparin 
and 5 ng of synthetic PAF, excised 24 hours (C) and 6 d (D) after the 
injection. By light microscopy  canalized vessels are seen already at 24 h 
and tend to form large aneurismatic vessels containing erythrocytes (E) 
after 6 d. (A-D,  x 100). 
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Figure  5.  Quanfitation of neovascularization  performed on hematoxylin- 
eosin-stained sections of Matrigel containing 64 U/ml heparin and 5 ng 
synthetic PAF (five experiments) or 1 ng biological PAF extracted and 
purified from five mice injected with Matrigel  containing TNF-c~, and 
effect of WEB 2170 (see Materials and Methods).  Mice were killed 6 d 
after the injection of Matrigel. 
with  TNF-o~  and  purified  from  the  Matrigel  plugs  was 
sufficient to elicit a direct angiogenic response (Fig. 5). This 
angiogenic response was completely prevented by the receptor 
antagonist WEB 2170 (Fig. 5). The time course study indi- 
cated that the angiogenic effect of PAF occurred earlier than 
with TNF-ol, as canalized vessels containing erythrocytes and 
leukocytes were already observed at 24 h (Fig.  3 C). The an- 
giogenic effect of PAF was not associated with an inflamma- 
tory infiltration  of Matrigel. 
Discussion 
The results of this present study indicate that PAF is a medi- 
ator of the angiogenic activity of TNF-ol. PAF may function 
either as an intercellular mediator or as an intracellular mes- 
senger (11).  Some of its actions are achieved at concentra- 
tions as low as 10-12 M  and include events relevant for the 
development of several pathological and physiological processes, 
such as inflammation, shock, embryogenesis, and cell differen- 
tiation (9-11,  27-29).  It was recently shown that  PAF acts 
through a specific receptor that belongs to the family of"ser- 
pentine" receptors containing  seven ol-helical  domains that 
weave in  and  out  of the plasma  membrane  (30,  31).  The 
receptor interacts with a G protein which activates a phos- 
phatidylinositol-specific phospholipase C (32). Potent antag- 
onists of PAF receptor have been described and are currently 
used in studies  of the pathophysiology of PAF. 
In vitro  studies  have established  an interaction  between 
TNF-c~ and PAF (6-8). TNF-c~ stimulates the synthesis of 
PAF by monocytes/macrophages,  polymorphonuclear  neu- 
trophils, and endothelial cells (6, 7). PAF, in turn, stimulates 
TNF-o~ production by monocytes/macrophages (8). It is there- 
fore possible that these two mediators may reciprocally in- 
teract during the development of several pathological and phys- 
iological  processes.  The  present  observation  that  PAF  is 
synthesized within Matrigel during vascularization induced 
by TNF-oe and that a specific PAF receptor antagonist, WEB 
2170, inhibits the angiogenic process, suggests that this phos- 
pholipid may act as a secondary mediator for TNF-oe. More- 
over,  PAF itself was shown to possess angiogenic activity. 
This study does not clarify the cellular source of PAF syn- 
thesized after stimulation with TNF-ce. However, the mono- 
cytes as well as the endothelial  cells,  which were the two 
cell populations detectable at 6 and 24 h when PAF was syn- 
thesized within  the Matrigel,  are both possible candidates 
for the synthesis of PAF induced by TNF-ce (6, 7). At the 
doses of TNF-ce used in this study, inflammatory cells other 
than monocytes were not detected within the Matrigel plugs. 
Therefore, it is unlikely that  PMN or lymphocytes are in- 
volved in the biosynthesis of PAF. Previous studies (5) have 
demonstrated that TNF-c~ can act as attractant  for mono- 
cytes and that TNF-c~-mediated angiogenesis is monocyte- 
dependent. The present observation that the angiogenic re- 
sponse increases  seven times when TNF-ol is doubled from 
5 to 10 ng, further supports the contention that TNF-oe acts 
via secondary mediators that are produced when TNF-c~ ex- 
ceeds a threshold concentration. Previous in vitro experiments 
have established that 10 ng/ml of TNF-c~ is an effective dose 
for initiating PAF synthesis from both macrophages and en- 
dothelial  cells  (6).  PAF  synthesized  by infiltrating  mono- 
cytes/macrophages and/or endothelial cells may either act as 
a  chemoattractant  or  as  a  mediator  that  amplifies  and 
propagates the reaction. Moreover, since cells that synthesize 
PAF have receptors for this phospholipid,  it is possible that 
the PAF receptor antagonist interferes with an autocrine modu- 
lation of the cell response to angiogenic cytokines. In addi- 
tion, PAF stimulates arachidonate hydrolysis from phospho- 
lipids,  thus initiating the synthesis of eicosanoids which, in 
turn, may induce additional PAF and TNF-ce production (8, 
33-35). In conclusion, the results of this study indicate that 
PAF mediates, at least in part, the in vivo angiogenic effect 
of TNF-oL. The definition of the relative contribution of the 
direct angiogenic effect of PAF and/or of its role in amplifying 
the response to other angiogenic cytokines, requires further 
investigations. 
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